{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:43:50Z","timestamp":1794321830751,"version":"4.9.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>\n                           <jats:italic toggle=\"yes\">CBFA2T3-GLIS2<\/jats:italic> is the most frequent chimeric oncogene identified to date in non\u2013Down syndrome acute megakaryocytic leukemia (AMKL), which is associated with extremely poor clinical outcome. The presence of this fusion gene is associated with resistance to high-intensity chemotherapy, including hematopoietic stem cell transplantation (HSCT), and a high cumulative incidence of relapse frequency. The clinical features and clinical effects of China Children\u2019s Leukemia Group\u2013acute myeloid leukemia (AML) 2015\/2019 regimens and haploidentical HSCT (haplo-HSCT) for treatment of 6 children harboring the <jats:italic toggle=\"yes\">CBFA2T3-GLIS2<\/jats:italic> fusion gene between January 2019 and December 2021 were retrospectively analyzed. The 6 patients included 4 boys and 2 girls with a median disease-onset age of 19.5 months (range: 6\u201367\u00a0mo) who were diagnosed with AMKL. Flow cytometry demonstrated CD41a, CD42b, and CD56 expression and lack of HLA-DR expression in all 6 patients. All the children were negative for common leukemia fusion genes by reverse transcription polymerase chain reaction, but positive for the <jats:italic toggle=\"yes\">CBFA2T3-GLIS2<\/jats:italic> fusion gene by next-generation sequencing and RNA sequencing. All patients received chemotherapy according to China Children\u2019s Leukemia Group\u2013AML 2015\/2019 regimens, and 4 achieved complete remission. Four children underwent haplo-HSCT with posttransplant cyclophosphamide-based conditioning; 3 had minimal residual disease negative (minimal residual disease &lt;0.1%) confirmed by flow cytometry at the end of the follow-up, with the remaining patient experiencing relapse at 12 months after transplantation. Transcriptome RNA sequencing is required for the detection of the <jats:italic toggle=\"yes\">CBFA2T3-GLIS2<\/jats:italic> fusion gene and for proper risk-based allocation of pediatric patients with AML in future clinical strategies. Haplo-HSCT with posttransplant cyclophosphamide\u2013based conditioning may improve survival in children with AMKL harboring the fusion gene.<\/jats:p>","DOI":"10.1097\/mph.0000000000002822","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T16:00:53Z","timestamp":1707148853000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene"],"prefix":"10.1097","volume":"46","author":[{"given":"Yu","family":"Du","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Pediatric Hematological Tumor Disease Laboratory, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Qi","sequence":"additional","affiliation":[{"name":"Pediatric Hematological Tumor Disease Laboratory, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[{"name":"Pediatric Hematological Tumor Disease Laboratory, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Pediatric Hematological Tumor Disease Laboratory, Wuhan Children\u2019s Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"De Rooij","year":"2017","journal-title":"Nat Genet"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood-2015-02-629204","article-title":"Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study","volume":"126","author":"Inaba","year":"2015","journal-title":"Blood"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-015-2383-2","article-title":"Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial","volume":"94","author":"Schweitzer","year":"2015","journal-title":"Ann Hematol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.clml.2018.12.011","article-title":"Outcome of childhood acute megakaryoblastic leukemia: Children\u2019s Cancer Hospital Egypt 57357 experience","volume":"19","author":"Maarouf","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/gcc.22444","article-title":"Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome","volume":"56","author":"Hara","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","article-title":"Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study","volume":"127","author":"De Rooij","year":"2016","journal-title":"Blood"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","article-title":"An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia","volume":"22","author":"Gruber","year":"2012","journal-title":"Cancer Cell"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1084\/jem.20121343","article-title":"Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models","volume":"209","author":"Thiollier","year":"2012","journal-title":"J Exp Med"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","article-title":"CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype","volume":"121","author":"Masetti","year":"2013","journal-title":"Blood"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bjh.16203","article-title":"Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup","volume":"188","author":"Hara","year":"2020","journal-title":"Br J Haematol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.15725","article-title":"CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity","volume":"184","author":"Masetti","year":"2019","journal-title":"Br J Haematol"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET Pediatric AML Study","volume":"26","author":"Smith","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cyto.a.24339","article-title":"CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript","volume":"99","author":"Zangrando","year":"2021","journal-title":"Cytometry A"},{"issue":"suppl 1","key":"R20-20250804","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1182\/blood-2019-125257","article-title":"Molecular MRD monitoring is feasible in the majority of children with AML and is highly predictive of outcome: results from the International MyeChild01 Study","volume":"134","author":"Jovanovic","year":"2019","journal-title":"Blood"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2016.151779","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant","volume":"102","author":"Ruggeri","year":"2017","journal-title":"Haematologica"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"e29221","DOI":"10.1002\/pbc.29221","article-title":"Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3\/GLIS2 childhood acute myeloid leukaemia","volume":"68","author":"Mishra","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2017.02.006","article-title":"ETO2-GLIS2 hijacks transcriptional complexes to drive cellular identity and self-renewal in pediatric acute megakaryoblastic leukemia","volume":"31","author":"Thirant","year":"2017","journal-title":"Cancer Cell"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-017-0396-0","article-title":"Hh\/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene","volume":"10","author":"Masetti","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"e157101","DOI":"10.1172\/JCI157101","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"132","author":"Le","year":"2022","journal-title":"J Clin Invest"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:04:35Z","timestamp":1754337875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002822","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"2023-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}